Petros Pharmaceuticals, Inc. (PTPI)

Petros Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	-	5.82	5.99	7.81
Revenue Growth (YoY)	-	-	-2.83%	-23.29%	-18.29%
Cost of Revenue	-	-	1.63	2.29	1.6
Gross Profit	-	-	4.19	3.7	6.21
Selling, General & Admin	4.64	4.63	9.26	12.21	15.59
Research & Development	-	-	2.41	1.74	1.79
Operating Expenses	4.64	4.63	14.95	19.55	24.26
Operating Income	-4.64	-4.63	-10.76	-15.85	-18.05
Interest Expense	-	-	-0.54	-0.6	-0.37
Interest & Investment Income	0.26	0.37	0.52	0.01	-
Other Non Operating Income (Expenses)	-0.12	3.55	2.62	0.46	-
EBT Excluding Unusual Items	-4.5	-0.71	-8.16	-15.97	-18.42
Asset Writedown	-	-	-	-7.46	-
Other Unusual Items	-	-	-	3.39	9.43
Pretax Income	-4.5	-0.71	-8.16	-20.04	-8.99
Earnings From Continuing Operations	-4.5	-0.71	-8.16	-20.04	-8.99
Earnings From Discontinued Operations	6.41	-13.61	-	-	-
Net Income	1.91	-14.32	-8.16	-20.04	-8.99
Preferred Dividends & Other Adjustments	45.6	12.48	5.65	-	-
Net Income to Common	-43.69	-26.8	-13.81	-20.04	-8.99
Shares Outstanding (Basic)	28	0	0	0	0
Shares Outstanding (Diluted)	28	0	0	0	0
Shares Change (YoY)	8641.96%	268.84%	5.11%	90.11%	103.90%
EPS (Basic)	-1.56	-83.47	-158.71	-241.98	-206.31
EPS (Diluted)	-1.56	-83.47	-158.71	-241.98	-206.31
Free Cash Flow	-6.73	-2.6	-7.63	-12.8	-11.86
Free Cash Flow Per Share	-0.24	-8.11	-87.62	-154.54	-272.32
Gross Margin	-	-	71.98%	61.79%	79.52%
Operating Margin	-	-	-184.84%	-264.44%	-231.05%
Profit Margin	-	-	-237.26%	-334.40%	-115.05%
Free Cash Flow Margin	-	-	-130.99%	-213.57%	-151.86%
EBITDA	-1.81	-1.8	-7.48	-10.25	-11.17
EBITDA Margin	-	-	-128.46%	-171.01%	-143.00%
D&A For EBITDA	2.83	2.83	3.28	5.6	6.88
EBIT	-4.64	-4.63	-10.76	-15.85	-18.05
EBIT Margin	-	-	-184.84%	-264.44%	-231.05%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.